Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: A Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial

Canadian Journal of Cardiology

Volumn 25, Issue 12, 2009, Pages

  Welsh, Robert C ^a   Sauriol, Luc ^b   Zhang, Zugui ^c   Kolm, Paul ^c   Weintraub, William S ^c   Theroux, Pierre ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Sanofi Aventis   (Canada)

^c Christiana Care Health System   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Acute myocardial infarction; Anticoagulation; Clinical trials; Coronary artery disease; Cost effectiveness

Indexed keywords

ENOXAPARIN; HEPARIN;

ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE REDUCTION; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE REPERFUSION; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; UNITED STATES;

EID: 73849115275     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70532-X     Document Type: Article

References (26)

1. Armstrong PW, Chang WC, Wallentin L, et al. Efficacy and safety of unfractionated heparin versus enoxaparin: A pooled analysis of ASSENT-3 and -3 PLUS data. CMAJ 2006;174:1421-6.
2. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366:1607-21.
3. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
4. Theroux P, Welsh RC. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol 2003;91:860-4.
5. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005;149:217-26.
6. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-88.
7. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993.
8. Régie de l'assurance maladie du Québec, Liste des medicaments, 2 juin, 2008.
9. Ontario Case Costing Initiative. 〈www.occp.com〉 (Version current at October 28, 2009).
10. Health Canada. Health Outcomes and Expenditure in Canada. 〈www.hc-sc.gc.ca〉 (Version current at October 28, 2009).
11. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:1851-8.
12. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002;23:458-66.
13. Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: A case study in atherothrombosis. Value Health 2004;7:627-35.
14. Ghali WA, Quan H, Brant R, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494-7.
15. Lee J, Yoshizawa C, Wilkens L, Lee HP. Covariance adjustment of survival curves based on Cox's proportional hazards regression model. Comput Appl Biosci 1992;8:23-7.
16. Makuch RW. Adjusted survival curve estimation using covariates. J Chronic Dis 1982;35:437-43.
17. Nieto FJ, Coresh J. Adjusting survival curves for confounders: A review and a new method. Am J Epidemiol 1996;143:1059-68.
18. Caro J, Migliaccio-Walle K, Ishak KJ, Weintraub WS. Estimating life-years lost due to atherothrombotic events: Flexible survival functions to use in disease modeling. J Am Coll Cardiol 2004;43:425A. (Abst)
19. Huynh T, O'Loughlin J, Joseph L, et al. Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: Results from the AMI-QUEBEC Study. CMAJ 2006;175:1527-32.
20. Armstrong PW. A comparison of pharmacologic therapy with/ without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: The WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27:1530-8.
21. Welsh RC, Travers A, Senaratne M, Williams R, Armstrong PW. Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center. Am Heart J 2006;152:1007-14.
22. Gibson CM, Murphy SA, Montalescot G, et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007;49:2238-46.
23. Zhang Z, Kolm P, Zhang W, et al. Cost effectiveness of enoxaparin in patients with ST-elevation myocardial infarction: Results from EXTRACT-TIMI 25. Circulation 2007;116:II-858.
24. Kaul P, Armstrong PW, Cowper PA, et al. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction. Am Heart J 2005;149:637-44.
25. Nutescu EA, Steinmetz PK. Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome. Expert Opin Pharmacother 2008;9:95-105.
26. Lamotte M, Annemans L, Kawalec P, Zoellner Y. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Pharmacoeconomics 2006;24:783-95.